Pantoprazole Inhibitor CAS No. 102625-70-7

Cat. No.	Name	Size	Price	Add Cart
KI0863	Pantoprazole	100 mg	$136
KI0863	Pantoprazole	500 mg	$392

Chemical Characteristic

Product Name	Pantoprazole
Synonyms	BY1023,SKF96022
CAS No.	102625-70-7
Molecular Weight	383.37
Formula	C₁₆H₁₅F₂N₃O₄S
Chemical Structure

Biological activities

Pantoprazole is a proton-pump inhibitor used in the treatment of gastric ulcers, gastro-esophageal reflux disease and Helicobacter pylori infections.^[1] Pantoprazole (40 µg/mL) decreases Ca²⁺ sensitivity of sarcoplasmic reticulum Ca²⁺ adenosine triphosphatase with a K_{δ of 395 nM. The EC50 for contractile depression of pantoprazole is 30.6 µg/mL in atrial human myocardium and 17.3 µg/mL in ventricular human myocardium, respectively. Pantoprazole depresses cardiac contractility in vitro by depression of Ca²⁺ signaling and myofilament activity. ^[2] Pantoprazole competitively inhibits CYP2C19 activity with Ki of 14 to 69 µM. Pantoprazole is a competitive inhibitor of both CYP2C9-catalyzed diclofenac 4閿?hydroxylation and CYP3A4-catalyzed midazolam 1閿?hydroxylation with Ki of 6 and 22 µM, respectively. ^[3] Pantoprazole-treated mice have a significantly elevated gastric pH in comparison to the gastric pH of the controls. ^[4]}

Protocols

Pantoprazole is dissolved in methanol and sequentially diluted with 40% methanol in 0.1 M Tris-hydrochloride buffer (pH=9). ^[3]

References

[1] Raffin RP, et al. Gastro-resistant microparticles containing sodium pantoprazole: stability studies and in vivo anti-ulcer activity. The Open Drug Delivery Journal, 2007, 1, 28-35. 閵嗏偓閵嗏偓 [2] Schillinger W, et al. Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms. Circulation. 2007, 116(1): 57-66. 閵嗏偓閵嗏偓 [3] Li XQ, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004, 32(8): 821-827. 閵嗏偓 [4] Stiefel U, et al. Suppression of gastric acid production by proton pump inhibitor treatment facilitates colonization of the large intestine by vancomycin-resistant Enterococcus spp. and Klebsiella pneumoniae in clindamycin-treated mice. Antimicrob Agents Chemother. 2006, 50(11): 3905-3907. 閵嗏偓閵嗏偓

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.